🚀 VC round data is live in beta, check it out!
Marinomed Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Marinomed Biotech and similar public comparables like Outlook Therapeutics, Lipum, Longeveron, BioXcel Therapeutics and more.
Marinomed Biotech Overview
About Marinomed Biotech
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
Founded
2006
HQ
Employees
47
Website
Sectors
Financials (LTM)
EV
$43M
Marinomed Biotech Financials
Marinomed Biotech reported last 12-month revenue of $10M and EBITDA of $19M.
In the same LTM period, Marinomed Biotech generated $19M in EBITDA and $13M in net income.
Revenue (LTM)
Marinomed Biotech P&L
In the most recent fiscal year, Marinomed Biotech reported revenue of $6M and EBITDA of ($6M).
Marinomed Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $10M | XXX | $6M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA | $19M | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | 200% | XXX | (107%) | XXX | XXX | XXX |
| EBIT Margin | 173% | XXX | (146%) | XXX | XXX | XXX |
| Net Profit | $13M | XXX | ($17M) | XXX | XXX | XXX |
| Net Margin | 142% | XXX | (311%) | XXX | XXX | XXX |
| Net Debt | — | — | $31M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Marinomed Biotech Stock Performance
Marinomed Biotech has current market cap of $33M, and enterprise value of $43M.
Market Cap Evolution
Marinomed Biotech's stock price is $16.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $43M | $33M | -0.2% | XXX | XXX | XXX | $-8.69 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMarinomed Biotech Valuation Multiples
Marinomed Biotech trades at 4.5x EV/Revenue multiple, and 2.3x EV/EBITDA.
EV / Revenue (LTM)
Marinomed Biotech Financial Valuation Multiples
As of April 18, 2026, Marinomed Biotech has market cap of $33M and EV of $43M.
Equity research analysts estimate Marinomed Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Marinomed Biotech has a P/E ratio of 2.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33M | XXX | $33M | XXX | XXX | XXX |
| EV (current) | $43M | XXX | $43M | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 7.8x | XXX | XXX | XXX |
| EV/EBITDA | 2.3x | XXX | (7.3x) | XXX | XXX | XXX |
| EV/EBIT | 2.6x | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 37.6x | XXX | XXX | XXX |
| P/E | 2.4x | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | 12.9x | XXX | (15.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Marinomed Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Marinomed Biotech Margins & Growth Rates
Marinomed Biotech's revenue in the last 12 month grew by 13%.
Marinomed Biotech's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Marinomed Biotech's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Marinomed Biotech's rule of X is 74% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Marinomed Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 63% | XXX | XXX | XXX |
| EBITDA Margin | 200% | XXX | (107%) | XXX | XXX | XXX |
| EBITDA Growth | (81%) | XXX | (528%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 50% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | 23% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 167% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Marinomed Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Marinomed Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Outlook Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Lipum | XXX | XXX | XXX | XXX | XXX | XXX |
| Longeveron | XXX | XXX | XXX | XXX | XXX | XXX |
| BioXcel Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tvardi Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Marinomed Biotech M&A Activity
Marinomed Biotech acquired XXX companies to date.
Last acquisition by Marinomed Biotech was on XXXXXXXX, XXXXX. Marinomed Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Marinomed Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMarinomed Biotech Investment Activity
Marinomed Biotech invested in XXX companies to date.
Marinomed Biotech made its latest investment on XXXXXXXX, XXXXX. Marinomed Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Marinomed Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Marinomed Biotech
| When was Marinomed Biotech founded? | Marinomed Biotech was founded in 2006. |
| Where is Marinomed Biotech headquartered? | Marinomed Biotech is headquartered in Austria. |
| How many employees does Marinomed Biotech have? | As of today, Marinomed Biotech has over 47 employees. |
| Is Marinomed Biotech publicly listed? | Yes, Marinomed Biotech is a public company listed on Wiener Börse. |
| What is the stock symbol of Marinomed Biotech? | Marinomed Biotech trades under MARI ticker. |
| When did Marinomed Biotech go public? | Marinomed Biotech went public in 2018. |
| Who are competitors of Marinomed Biotech? | Marinomed Biotech main competitors are Outlook Therapeutics, Lipum, Longeveron, BioXcel Therapeutics. |
| What is the current market cap of Marinomed Biotech? | Marinomed Biotech's current market cap is $33M. |
| What is the current revenue of Marinomed Biotech? | Marinomed Biotech's last 12 months revenue is $10M. |
| What is the current revenue growth of Marinomed Biotech? | Marinomed Biotech revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Marinomed Biotech? | Current revenue multiple of Marinomed Biotech is 4.5x. |
| Is Marinomed Biotech profitable? | Yes, Marinomed Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Marinomed Biotech? | Marinomed Biotech's last 12 months EBITDA is $19M. |
| What is Marinomed Biotech's EBITDA margin? | Marinomed Biotech's last 12 months EBITDA margin is 200%. |
| What is the current EV/EBITDA multiple of Marinomed Biotech? | Current EBITDA multiple of Marinomed Biotech is 2.3x. |
| What is the current FCF of Marinomed Biotech? | Marinomed Biotech's last 12 months FCF is $3M. |
| What is Marinomed Biotech's FCF margin? | Marinomed Biotech's last 12 months FCF margin is 35%. |
| What is the current EV/FCF multiple of Marinomed Biotech? | Current FCF multiple of Marinomed Biotech is 12.9x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.